XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Sector

Healthcare

Industry

Biotechnology

Country

United States

Exchange

Nasdaq

CEO

Sushma Shivaswamy

Employees

92

IPO date

15 Apr 2015

ISIN

CA98400H1029

Website

xbiotech.com